Moderna, Inc. (MRNA)
Moderna Stock: How Far Can The Flu Shot Fly?
Moderna (MRNA) – a developer of mRNA-focused therapeutics and vaccines – has recorded a 6-day winning streak, accumulating gains of 25% during this time. The company's market capitalization has increased by approximately $4.0 billion over the past 6 days and now sits at $20 billion.
Moderna Stock Jumps After FDA Reverses Course on Flu Shot
MRNA stock rises 6% as the FDA agrees to review its flu vaccine filing after a surprise reversal, with a decision expected by Aug. 5, 2026.
Moderna's investigational flu vaccine moves forward in FDA review
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) announced that the US Food and Drug Administration (FDA) will initiate review of its investigational seasonal influenza vaccine, mRNA-1010, following a Type A meeting between the company and the agency. Shares of Moderna added 6.5% at about $47 on the update.
Moderna Shares Rally 6% After FDA Reverses Decision Not To Review Flu Vaccine
The FDA's “refuse-to-file” letter sent to reject Moderna's application is a rarity: A 2021 study found that 4% of the nearly 2,500 applications submitted to the agency receive such letters, many of which cited drug efficacy, safety and quality.
Moderna got the FDA to change its mind and review its flu vaccine after some concessions
Moderna's stock was surging after the FDA said it would review the biotech's flu-vaccine candidate, a week after it had refused to do so.
Moderna Stock Pops as FDA Application Moves Forward
Pharma giant Moderna Inc (NASDAQ:MRNA) is enjoying a boost today, after the U.S. Food & Drug Administration (FDA) accepted the company's flu vaccine application for review.
FDA reverses decision not to review Moderna's new flu vaccine
The Food and Drug Administration has reversed its decision not to review a new flu vaccine from Moderna, the pharmaceutical company said Wednesday.
The FDA reversed course and agreed to begin a review of Moderna's seasonal flu shot
The company's mRNA flu shot, if approved, could be available for the 2026-27 flu season.
US FDA to initiate review of Moderna's influenza vaccine
Moderna said on Wednesday the U.S. Food and Drug Administration has accepted its application to review its influenza vaccine candidate.
Moderna's Shares Climb 5.3% as Investors Revisit Biotech Leaders
MRNA shares jumped 5.3% as investors rotated into large-cap biotech, betting on its expanding pipeline in volatile trade.
Moderna, Inc. (MRNA) Q4 2025 Earnings Call Transcript
Moderna, Inc. (MRNA) Q4 2025 Earnings Call Transcript
Moderna Q4 Loss Narrower-Than-Expected, Sales Beat Estimates
MRNA posts a narrower Q4 loss and beats sales estimates, despite a 30% revenue drop, while advancing its pipeline and reaffirming 2026 outlook.
